Syngenta signs global commercial agreement with Novozymes

          Syngenta signs global commercial agreement with Novozymes

- Addition of a key biofungicide to complement Syngenta's offer

- Novel control of damaging diseases across various crops

- Exclusive global marketing and distribution agreement

PR Newswire

BASEL, Switzerland, Oct. 26, 2012

BASEL, Switzerland, Oct. 26, 2012 /PRNewswire/ -- Syngenta and Novozymes today
announced an exclusive global marketing and distribution agreement to
commercialize Taegro^®, a fermented biological fungicide based on a naturally
occurring bacterium Bacillus subtilis. It offers growers broad-spectrum
disease control at very low application rates in a variety of crops. Its
multiple modes of action make it highly complementary to Syngenta's extensive
fungicide portfolio.

In April, Syngenta and Novozymes announced a global agreement to commercialize
the Novozymes technology JumpStart^®, a seed-applied biological that increases
phosphate solubility in the soil.

John Atkin, Chief Operating Officer, said: "We are delighted to enter into
another agreement to commercialize a Novozymes technology. Having worldwide
commercial rights for Taegro will further strengthen our ability to offer
high-performing integrated crop solutions."

Thomas Videbaek, Executive Vice President Novozymes, commented: "This
collaboration matches Syngenta's global market strength and leading position
within fungicides and integrated solutions with Novozymes' deep know-how on
sustainable, bio-based technologies."

Expanding the existing registrations of Taegro in the U.S., the companies aim
to offer the technology to growers around the world for use on a broad range
of crops.

Financial details about the agreement were not disclosed.

Syngenta is one of the world's leading companies with more than 26,000
employees in over 90 countries dedicated to our purpose: Bringing plant
potential to life. Through world-class science, global reach and commitment to
our customers we help to increase crop productivity, protect the environment
and improve health and quality of life. For more information about us please
go to

CautionaryStatement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by
terminology such as 'expect', 'would', 'will', 'potential', 'plans',
'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such
statements may be subject to risks and uncertainties that could cause the
actual results to differ materially from these statements. We refer you to
Syngenta's publicly available filings with the U.S. Securities and Exchange
Commission for information about these and other risks and uncertainties.
Syngenta assumes no obligation to update forward-looking statements to reflect
actual results, changed assumptions or other factors. This document does not
constitute, or form part of, any offer or invitation to sell or issue, or any
solicitation of any offer, to purchase or subscribe for any ordinary shares in
Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on
in connection with, any contract therefor.


Media Office                      Media contact:
                                                      Jennifer Gough
Switzerland                       Paul Barrett
                                                      Switzerland +41 61 323
Tel: +41 61 323    Switzerland +41 61 5059
2323                              323 2323
                                                      USA +1 202
Fax: +41 61 323                        737 6521

SOURCE Syngenta

Press spacebar to pause and continue. Press esc to stop.